MARKET

AYTU

AYTU

Aytu BioPharma Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.130
+0.100
+3.30%
Closed 18:53 09/17 EDT
OPEN
3.050
PREV CLOSE
3.030
HIGH
3.150
LOW
3.030
VOLUME
662.05K
TURNOVER
--
52 WEEK HIGH
14.00
52 WEEK LOW
3.020
MARKET CAP
78.78M
P/E (TTM)
-1.1353
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 5d ago
Aytu BioPharma Announces Formation Of New Scientific Advisory Board To Support Development Of AR101 For Vascular Ehlers-Danlos Syndrome
 Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the formation of its Scientific Advisory Board,
Benzinga · 09/09 12:11
Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome
Chaired by Dr. Hal Dietz and joined initially by Dr. Xavier Jeunemaitre, Dr. Shaine Morris, Dr. Bart Loeys, and Dr. Peter Byers with additional advisors to be added
ACCESSWIRE · 09/09 12:01
Aytu BioPharma to Present at Upcoming September Investor Conferences
ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Ex...
ACCESSWIRE · 09/07 12:00
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
2 Falling Knives to Catch
GuruFocus News · 08/17 11:05
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AYTU. Analyze the recent business situations of Aytu BioPharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AYTU stock price target is 17.50 with a high estimate of 24.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 86
Institutional Holdings: 5.93M
% Owned: 23.55%
Shares Outstanding: 25.17M
TypeInstitutionsShares
Increased
15
522.46K
New
13
934.63K
Decreased
16
1.69M
Sold Out
24
946.54K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Chief Executive Officer/Director
Joshua Disbrow
Chief Financial Officer/Treasurer/Secretary
Richard Eisenstadt
Director
Jerry McLaughlin
Independent Director
Gary Cantrell
Independent Director
Carl Dockery
Independent Director
John Donofrio
Independent Director
Beth Hecht
Independent Director
Michael Macaluso
No Data
About AYTU
Aytu Biopharma, Inc., formerly Aytu BioScience, Inc., is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The Company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. It markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The Company's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.

Webull offers kinds of Aytu Biopharma Inc stock information, including NASDAQ:AYTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AYTU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AYTU stock methods without spending real money on the virtual paper trading platform.